论文部分内容阅读
目的分析研讨长春瑞滨联合顺铂化疗治疗蒽环类耐药乳腺癌疾病的临床效果。方法共80例研讨对象,均为2013年4月至2016年5月期间收治的蒽环类耐药乳腺癌患者,按随机法分为对照组(40例,顺铂+多西他赛)和研究组(40例,长春瑞滨+顺铂),观察治疗效果,并分析。结果研究组不良反应总发生率(10%)比对照组(30%)显著降低,组间数据有统计学意义(P<0.05)。对比两组患者SF-36评分,包含精神功能、社会功能、心理功能、躯体功能等状况,研究组均高于对照组,组间数据有统计学意义(P<0.05)。结论临床治疗蒽环类耐药乳腺癌患者应用NP方案,安全性高,不良反应少,生活质量高,值得临床推广。
Objective To study the clinical effect of vinorelbine combined with cisplatin in the treatment of anthracycline-resistant breast cancer. Methods Totally 80 subjects were all treated with anthracycline-resistant breast cancer from April 2013 to May 2016. They were randomly divided into control group (n = 40), cisplatin plus docetaxel Study group (40 cases, vinorelbine + cisplatin), to observe the therapeutic effect, and analysis. Results The total adverse reaction rate (10%) in the study group was significantly lower than that in the control group (30%). The data of the two groups were statistically significant (P <0.05). The scores of SF-36 in two groups were compared, including mental function, social function, psychological function and somatic function. The study group was higher than the control group, and the data of the two groups were statistically significant (P <0.05). Conclusion Clinical application of NP regimen in patients with anthracycline-resistant breast cancer is safe, with few adverse reactions and high quality of life. It is worthy of clinical promotion.